Agencia Lei Va Hong
Concise Prescribing Info
Abacavir sulfate
Antiretroviral combination therapy for the treatment of HIV infection in adults, adolescent & childn.
Dosage/Direction for Use
Adult, adolescent & childn at least 25 kg 600 mg daily [either 300 mg (1 tab or 15 mL) bd or 600 mg (2 tab or 30 mL) once daily]. Tab Childn weighing ≥20 kg to <25 kg 450 mg daily [either 150 mg (½ tab) in the morning & 300 mg (1 tab) in the evening, or 450 mg (1½ tab) once daily]; 14 to <20 kg 300 mg daily [either as 150 mg (½ tab) bd or 300 mg (1 tab) once daily]. Oral soln Childn weighing <25 kg, ≥1 yr 8 mg/kg bd or 16 mg/kg once daily. Max: 600 mg (30 mL) daily, 3 mth to 1 yr 8 mg/kg bd, if not feasible, consider 16 mg/kg once daily.
May be taken with or without food: For patients unable to swallow, crush tab & add to a small amount of semi-solid food or liqd then, consume immediately.
Special Precautions
Risk of hypersensitivity reactions. Do not initiate in patients w/ a positive HLA-B*5701 status, nor in patients w/ a negative HLA-B*5701 status who had a suspected abacavir hypersensitivity reaction on a previous abacavir-containing regimen. Mitochondrial dysfunction in HIV-negative infants exposed in utero &/or post-natally to nucleoside analogues. Increase in wt & in levels of blood lipids & glucose may occur. Pancreatitis; immune reactivation syndrome; osteonecrosis. Minimize all modifiable risk factors for MI before commencing therapy. High rate of virological failure & of emergence of resistance at an early stage when combined w/ tenofovir disoproxil fumarate & lamivudine as once daily regimen. Opportunistic infections may continue to develop. Increased risk of severe & potentially fatal hepatic adverse events in patients w/ chronic hepatitis B or C treated w/ combination antiretroviral therapy. Patients w/ pre-existing liver dysfunction, including chronic active hepatitis. Should not be administered to patients w/ end-stage renal disease. Not recommended in patients w/ moderate or severe hepatic impairment. Pregnancy & lactation. Elderly. Childn <3 mth. Oral soln: Rare hereditary problems of fructose intolerance. Contains methyl parahydroxybenzoate & propyl parahydroxybenzoate.
Adverse Reactions
Anorexia; headache; nausea, vomiting, diarrhoea; rash (w/o systemic symptoms); fever, lethargy, fatigue.
Drug Interactions
Slightly decreased plasma conc w/ potent enzymatic inducers (eg, rifampicin, phenobarb & phenytoin). Reduced Cmax & delayed tmax w/ methadone. Possible interaction w/ retinoids.
MIMS Class
ATC Classification
J05AF06 - abacavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Ziagen oral soln 20 mg/mL
240 mL x 1's
Ziagen tab 300 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in